BR112016023554A2 - novos compostos macrocíclicos - Google Patents

novos compostos macrocíclicos

Info

Publication number
BR112016023554A2
BR112016023554A2 BR112016023554A BR112016023554A BR112016023554A2 BR 112016023554 A2 BR112016023554 A2 BR 112016023554A2 BR 112016023554 A BR112016023554 A BR 112016023554A BR 112016023554 A BR112016023554 A BR 112016023554A BR 112016023554 A2 BR112016023554 A2 BR 112016023554A2
Authority
BR
Brazil
Prior art keywords
macrocyclic compounds
compounds
new macrocyclic
preparation
general formula
Prior art date
Application number
BR112016023554A
Other languages
English (en)
Other versions
BR112016023554B1 (pt
Inventor
Scholz Arne
Stegmann Christian
Chen Gang
Siemeister Gerhard
Xi Jiajun
Zheng Kunzeng
Lienau Philip
Wasnaire Pierre
Gao Ping
Bömer Ulf
Lücking Ulrich
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52824234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016023554(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of BR112016023554A2 publication Critical patent/BR112016023554A2/pt
Publication of BR112016023554B1 publication Critical patent/BR112016023554B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/16—Halogenated acetic acids
    • C07C53/18—Halogenated acetic acids containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

novos compostos macrocíclicos. a presente invenção está relacionada a novos compostos macrocíclicos da fórmula geral (i) conforme descrito e definido neste documento e métodos para sua preparação, seu uso para tratamento e/ou profilaxia de distúrbios, em particular distúrbios hiperproliferativos e/ou doenças infecciosas induzidas por vírus e/ou doenças cardiovasculares. a invenção também está relacionada a compostos intermediários úteis na preparação dos compostos citados da fórmula geral (i).
BR112016023554-1A 2014-04-11 2015-04-08 Novos compostos macrocíclicos BR112016023554B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2014/000392 2014-04-11
CN2014000392 2014-04-11
PCT/EP2015/057546 WO2015155197A1 (en) 2014-04-11 2015-04-08 Novel macrocyclic compounds

Publications (2)

Publication Number Publication Date
BR112016023554A2 true BR112016023554A2 (pt) 2017-08-15
BR112016023554B1 BR112016023554B1 (pt) 2023-03-14

Family

ID=52824234

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016023554-1A BR112016023554B1 (pt) 2014-04-11 2015-04-08 Novos compostos macrocíclicos

Country Status (28)

Country Link
US (1) US9963464B2 (pt)
EP (1) EP3129387B1 (pt)
JP (1) JP6605493B2 (pt)
KR (1) KR102383938B1 (pt)
CN (1) CN106459084B (pt)
AP (1) AP2016009483A0 (pt)
AR (1) AR099999A1 (pt)
AU (1) AU2015243585B2 (pt)
BR (1) BR112016023554B1 (pt)
CA (1) CA2945237C (pt)
CL (1) CL2016002577A1 (pt)
CR (1) CR20160471A (pt)
CU (1) CU24399B1 (pt)
DO (1) DOP2016000278A (pt)
EA (1) EA032541B1 (pt)
ES (1) ES2743799T3 (pt)
IL (1) IL247966B (pt)
MX (1) MX2016013362A (pt)
PE (1) PE20161379A1 (pt)
PH (1) PH12016501968A1 (pt)
SG (1) SG11201608430RA (pt)
SV (1) SV2016005301A (pt)
TN (1) TN2016000435A1 (pt)
TW (1) TW201623312A (pt)
UA (1) UA119349C2 (pt)
UY (1) UY36072A (pt)
WO (1) WO2015155197A1 (pt)
ZA (1) ZA201607765B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10717749B2 (en) 2015-09-29 2020-07-21 Bayer Pharma Aktiengesellschaft Macrocyclic sulfondiimine compounds
JP6888000B2 (ja) * 2015-10-08 2021-06-16 バイエル ファーマ アクチエンゲゼルシャフト 新規な修飾された大環状化合物
WO2017182625A1 (en) * 2016-04-22 2017-10-26 Astrazeneca Ab Macrocyclic mcl1 inhibitors for treating cancer
CA3040815C (en) * 2016-10-20 2021-07-20 Steven Martin Evans Anti-proliferative agents for treating pah
US11242356B2 (en) 2017-03-28 2022-02-08 Bayer Aktiengesellschaft PTEFb inhibiting macrocyclic compounds
ES2900199T3 (es) 2017-03-28 2022-03-16 Bayer Ag Novedosos compuestos macrocíclicos inhibidores de PTEFB
CN109251212A (zh) * 2017-07-14 2019-01-22 上海长森药业有限公司 内环硫醚酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途
CN111434665B (zh) * 2019-01-11 2023-03-10 上海长森药业有限公司 内环硫脒酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途
CN112321604A (zh) * 2019-08-05 2021-02-05 华东理工大学 大环类jak2抑制剂及其应用
WO2023057812A1 (en) 2021-10-04 2023-04-13 Vincerx Pharma Gmbh Compounds, pharmaceutical compositions, and methods for the treatment, prevention, or management of hyperproliferative disorder

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2324981T3 (es) 2000-12-21 2009-08-21 Smithkline Beecham Corporation Pirimidinaminas como moduladores de la angiogenesis.
DE10239042A1 (de) * 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
DE10349423A1 (de) 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
MX2007007272A (es) 2004-12-17 2007-07-11 Astrazeneca Ab 4-(4-imidazol-4-il)pirimidin-2-ilamino)benzamidas como inhibidores de cdk.
DE102006042143A1 (de) 2006-09-08 2008-03-27 Bayer Healthcare Aktiengesellschaft Neue substituierte Bipyridin-Derivate und ihre Verwendung
WO2008060248A1 (en) 2006-11-15 2008-05-22 S*Bio Pte Ltd. Indole sustituted pyrimidines and use thereof in the treatment of cancer
AU2007336918A1 (en) 2006-12-22 2008-07-03 Novartis Ag Indol-4-yl-pyrimidinyl-2-yl-amine derivatives and use thereof as cyclin dependant kinase inhibitors
AU2007336933A1 (en) 2006-12-22 2008-07-03 Novartis Ag Heteroaryl-heteroaryl compounds as CDK inhibitors for the treatment of cancer, inflammation and viral infections
EP2137166B1 (en) 2007-04-24 2012-05-30 Ingenium Pharmaceuticals GmbH 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases
US8436007B2 (en) 2007-04-24 2013-05-07 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
WO2008129071A1 (en) 2007-04-24 2008-10-30 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
WO2008132138A1 (en) 2007-04-25 2008-11-06 Ingenium Pharmaceuticals Gmbh Derivatives of 4,6-disubstituted aminopyrimidines
WO2009029998A1 (en) 2007-09-06 2009-03-12 Cytopia Research Pty Ltd Retrometabolic compounds
GB0805477D0 (en) 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
US8415381B2 (en) 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
KR101752519B1 (ko) 2010-03-22 2017-06-29 리드 디스커버리 센터 게엠베하 제약 활성 이치환된 트리아진 유도체
US9242937B2 (en) 2011-03-02 2016-01-26 Bayer Intellectual Property Gmbh Pharmaceutically active disubstituted pyridine derivatives
EP2527332A1 (en) 2011-05-24 2012-11-28 Bayer Intellectual Property GmbH 4-Aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group as CDK9 inhibitors
CN103917527B (zh) * 2011-09-16 2017-05-31 拜耳知识产权有限责任公司 二取代的5‑氟‑嘧啶
EP2755948B1 (en) 2011-09-16 2016-05-25 Bayer Intellectual Property GmbH Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group
CA2888381A1 (en) 2012-10-18 2014-04-24 Bayer Pharma Aktiengesellschaft 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfone group
ES2622583T3 (es) 2012-11-15 2017-07-06 Bayer Pharma Aktiengesellschaft 4-(Orto)-fluorofenil-5-fluoropirimidin-2-ilaminas que contienen un grupo sulfoximina
KR102242871B1 (ko) 2012-11-15 2021-04-20 바이엘 파마 악티엔게젤샤프트 술폭시민 기를 함유하는 5-플루오로-n-(피리딘-2-일)피리딘-2-아민 유도체
CN105492438B (zh) 2013-07-04 2018-08-07 拜耳医药股份有限公司 磺亚胺取代的5-氟-n-(吡啶-2-基)吡啶-2-胺衍生物以及其作为cdk9激酶抑制剂的用途
CA2942119A1 (en) 2014-03-13 2015-09-17 Bayer Pharma Aktiengesellschaft 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group

Also Published As

Publication number Publication date
KR20160136449A (ko) 2016-11-29
IL247966B (en) 2021-02-28
JP2017510598A (ja) 2017-04-13
CA2945237C (en) 2022-09-06
AU2015243585A1 (en) 2016-10-13
ZA201607765B (en) 2022-09-28
UY36072A (es) 2015-11-30
CA2945237A1 (en) 2015-10-15
KR102383938B1 (ko) 2022-04-08
UA119349C2 (uk) 2019-06-10
MX2016013362A (es) 2017-02-09
TW201623312A (zh) 2016-07-01
IL247966A0 (en) 2016-11-30
TN2016000435A1 (en) 2018-04-04
EP3129387B1 (en) 2019-06-26
CR20160471A (es) 2016-12-21
SV2016005301A (es) 2018-03-12
AU2015243585B2 (en) 2019-08-01
BR112016023554B1 (pt) 2023-03-14
EP3129387A1 (en) 2017-02-15
EA032541B1 (ru) 2019-06-28
CL2016002577A1 (es) 2017-04-07
CU20160152A7 (es) 2017-04-05
US20170029439A1 (en) 2017-02-02
ES2743799T3 (es) 2020-02-20
PE20161379A1 (es) 2017-01-15
SG11201608430RA (en) 2016-11-29
JP6605493B2 (ja) 2019-11-13
CN106459084B (zh) 2019-04-19
AP2016009483A0 (en) 2016-10-31
WO2015155197A1 (en) 2015-10-15
PH12016501968A1 (en) 2016-12-19
AR099999A1 (es) 2016-08-31
US9963464B2 (en) 2018-05-08
CN106459084A (zh) 2017-02-22
DOP2016000278A (es) 2016-11-15
EA201692034A1 (ru) 2017-04-28
CU24399B1 (es) 2019-04-04

Similar Documents

Publication Publication Date Title
BR112016023554A2 (pt) novos compostos macrocíclicos
CL2018000039A1 (es) Derivados de oxopiridina sustituidos
BR112017002221A2 (pt) 2-(morfolin-4-il)-1,7-naftiridinas
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201591524A1 (ru) Производные 2-аминопиримидина для лечения вирусных инфекций
EA201691582A1 (ru) Новые фармацевтические препараты
EA202090547A2 (ru) Макроциклические деаза-оксипурины для лечения вирусных инфекций
UA113651C2 (xx) Макроциклічні пурини для лікування вірусних інфекцій
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
MX2016002241A (es) Alcoholes de alquinilo y metodos de uso.
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
EA201690687A1 (ru) Ингибиторы репликации вируса иммунодефицита
MX2015009444A (es) Trampas novedosas en el tratamiento de la degeneracion macular.
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
EA201790519A1 (ru) Терапевтические соединения в качестве ингибиторов рецептора орексина-1
BR112017003705A2 (pt) compostos contendo nitrogênio tricíclicos para o tratamento de infecção por neisseria gonorrhoea
UY36938A (es) Nuevos compuestos macrocíclicos modificados
BR112016016853A2 (pt) Compostos contendo nitrogênio, seu uso e seu processo de preparação, composição farmacêutica e seu uso
UY36868A (es) Composiciones para tratamiento de enfermedades mediadas por interleuquina 5 (il-5)
UY36923A (es) Nuevos compuestos macrocíclicos de sulfondiimina
BR112016020260A8 (pt) uso de um composto na fabricação de um medicamento para tratar uma doença colestática intra-hepática
BR112016006317A2 (pt) Derivados de fenilalanina substituída

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/04/2015, OBSERVADAS AS CONDICOES LEGAIS